Details for Patent: 12,076,319
✉ Email this page to a colleague
Which drugs does patent 12,076,319 protect, and when does it expire?
Patent 12,076,319 protects VOYDEYA and is included in one NDA.
This patent has three patent family members in three countries.
Drugs Protected by US Patent 12,076,319
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-001 | Mar 29, 2024 | RX | Yes | No | 12,076,319 | ⤷ Subscribe | TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB | ⤷ Subscribe | ||||
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-002 | Mar 29, 2024 | RX | Yes | Yes | 12,076,319 | ⤷ Subscribe | TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,076,319
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| China | 111163767 | ⤷ Subscribe | |||
| European Patent Office | 3661493 | ⤷ Subscribe | |||
| World Intellectual Property Organization (WIPO) | 2019028284 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
